Abstract: Sarcomas are an uncommon group of over 50 different individual histological malignancies arising from mesenchymal (non-epithelial or connective) tissues. Overall, they constitute 1% of human malignancies with an annual incidence rate of fewer than 5 patients per million. Sarcoma may arise from any mesenchymal cell lineages including fat, muscle, or other connective tissues. Due to the rarity of these groups of malignancies, many subtypes were, and still today, are managed as a single entity. This review focused on soft tissue sarcomas with an emphasis on how to integrate therapies for patients with this rare disorder. The role for surgical resection in cure and palliation as well as the relative benefits of adjuvant therapies such as chemotherapy and radiation therapy are discussed.
Introduction
Sarcomas are an extremely uncommon group of malignancies arising from mesenchymal (non-epithelial or connective) tissues. Overall, they constitute 1% of human malignancies with an annual incidence rate of fewer than 5 patients per million (1, 2) . Sarcoma may arise from any mesenchymal cell lineages including fat, muscle, or connective tissue. Overall, over 50 different individual histological sarcoma subtypes have been described. Due to the rarity of these groups of malignancies, many subtypes were, and still today to a large extent, are managed as a single entity.
Overall patients with soft tissue sarcoma (STS) will present with either localized or metastatic disease. Approaches for localized disease generally primarily focus on the use of surgical extirpation to remove the tumor; ideally with a margin-negative resection, usually without lymph node resection. Such surgeries can result in significant overall cure rates. In the setting of localized STS, radiation therapy may serve as an adjunct for local control in the setting of close margins with high-grade disease (3) . Based upon tumor type and grade, chemotherapy is an additional adjunct that remains somewhat controversial for resectable disease depending upon the specific tumor type. Chemotherapy, however, is certainly beneficial for some subtypes and, like radiation therapy, most likely beneficial for higher-grade tumors. The role of chemotherapy, nonetheless, although clearly beneficial for some high-grade STS subtypes, remains somewhat controversial as both phase II and populationbased studies demonstrate minimal to no benefit in overall survival on top of surgery and no improvement in survival for many subtypes with metastatic disease (4) .
Although the role of adjuvant therapies is modest in the management of STS, over half of all STS patients will survive beyond 5-years following presentation. As targeted therapies have been introduced, survival rates have dramatically improved for certain subtypes, such as GIST. For other STS types outcomes have not changed (5) (6) (7) . This review focuses on integrating therapies around the treatment of the STS patient with a focus on overall management and surgical considerations. (9, 10) . Of truncal sarcomas, thoracic STS tend to present at the smallest size, as these masses frequently will cause organ compression resulting in dyspnea or cardiac function problems. For both abdominal and retroperitoneal tumors, larger sizes are more common, as these locations can be associated with minimal symptoms even at very large sizes. Tumors arising in the retroperitoneum frequently are the least symptomatic and present on average with the largest tumor sizes. In fact, over two-thirds of retroperitoneal tumors present over 10 cm in diameter with 20-30 cm masses not being infrequent (11, 12) .
STS types by location
Regarding distribution, STS in adults arise most commonly in the trunk or retroperitoneum (62%), extremity (30%) or head and neck area (7%). Among STS, the most common types are leiomyosarcoma (LMS) and gastrointestinal stromal tumors (GIST) (together accounting for 40% of STS), followed by undifferentiated pleomorphic sarcoma/ malignant fibrohistiosarcoma (MFH; 30%), liposarcoma (20%), fibrosarcoma (6%) and other tumor types (4%) (1, 2, 11, 13) . In head and neck tumors, MFH is most common sarcoma (8, 14) . In the trunk, LMS/GIST are the most common while in the retroperitoneum, liposarcoma is the most common (13). In adults, sarcoma incidence has been noted to be increasing in the population with an incidence of 30-35 cases per 1,000,000 population. This increase is likely, in part, related to the increasing utilization of cross-sectional imaging revealing incidental slow-growing masses. Risk of developing sarcoma is more common after age 50 years with a stable incidence being observed after that age (2, 10, 13) .
Is there a need for tissue diagnosis?
The great variety of tumor types and the potential for different optimal therapeutic approaches support the routine biopsy to obtain a clear histologic diagnosis prior to initiating treatment. Differential diagnosis may, based upon cross-sectional imaging information, include inflammatory, benign, locally aggressive tumors, STS and other malignancies. Biopsy, either obtained by core-needle or open techniques may prevent surgery in instances where a mass may not represent sarcoma or may allow initiation of alternative therapies such as a targeted neoadjuvant approach potentially as part of a clinical trial. That being said, in instances where the diagnosis can be accurately ascertained by cross-sectional imaging, where severe symptoms exist or if the differential includes tumors that would all benefit from resection, then a preoperative tissue diagnosis may not be necessary prior to resection. Examples of this would include large retroperitoneal masses, particularly those with a density consistent with fat, hypervascular gastric masses consistent with GIST, or instances of a likely sarcoma with intestinal obstruction. Care should be exercised if resection is planned without a prior tissue diagnosis, as conditions such as lymphoma may mimic those of sarcoma in many locations including the pelvis, groin and retroperitoneum (15) (16) (17) (18) .
Biopsy approach
For patients where a core or open biopsy is planned, consideration as to how to approach the tumor biopsy is important. Generally, regardless if an open or core biopsy is planned, the tract should be placed in such a way as it might be excised during the definitive resection to both hopefully optimize local control and prevent tumor seeding (19) .
Some authors prefer a core biopsy to make a diagnosis of STS. This certainly is useful for cases of intestinal sarcoma where a diagnosis may be unclear or targeted neoadjuvant chemotherapy for GIST planned. Core biopsy is also an excellent first approach in settings where a local recurrence of disease or metastases is suspected. Furthermore, if preoperative concerns regarding subjecting a patient to open biopsy due to their overall health, comorbidities, or tumor location may also justify a core biopsy. In such cases a core biopsy may allow a rapid diagnosis of recurrence and allow implementation of a variety of non-surgical therapies if warranted (16, (20) (21) (22) . Many clinicians prefer an open biopsy to a core biopsy especially in locations where an open biopsy can be easily and safely obtained. This is mainly because it can be hard to make the diagnosis on core biopsy due to large amount of necrotic tissue. Furthermore, the limited tissue provided by a core biopsy may miss highergrade components of the tumor. Nonetheless, a core biopsy may be used as a first attempt to obtaining a diagnosis if it may be obtained expediently. The reader is cautioned, however, to recognize that if obtaining a core biopsy might ultimately delay diagnosis and implementation of care, consideration to immediately proceeding to a definitive open biopsy may be optimal (23) (24) (25) .
In the extremity and more superficial areas of the trunk, biopsy for patients with a new soft tissue mass is generally best accomplished by open biopsy. Considerations regarding the incision would be to place it in such a way as to allow easy re-excision of the mass during definitive care. Generally this is done by making the incision along the long axis of an extremity, overlying the mass of interest. Transverse incisions over the extremity may be suboptimal as they may be difficult to fully re-excise and may complicate subsequent incisional closure and healing due to blood-flow disruption. Usually biopsies are planned as incisional rather than excisional, as total removal of a mass at initial biopsy may make subsequent margin-negative surgery difficult to achieve. Nonetheless, excisional biopsy is reasonable and may be a better option for smaller tumors such as those under 5 cm. These smaller masses frequently will prove not to be malignant and may allow a patient to not undergo a second procedure (25, 26) .
Localized disease: the principles of surgical resection
For STS, surgery has been recognized as the main therapy for patients, and one that can provide the most significant chance for palliation, long-term survival and the only therapy associated with cure. Although a multidisciplinary approach is necessary in most cases, the management of resectable STS should have key input from the surgeon due to the critical role for surgery in optimizing the pre-operative planning and approach to resection (3, 12, 14, 25, 27) .
Theoretical operative objectives for all STS are similar and focus on obtaining a margin-negative resection generally without need for lymphadenectomy. Many experts suggest that 1-2 cm negative margins or inclusion of an additional plane of uninvolved tissue should be the goal of surgery (3, (28) (29) (30) . However, some studies suggest that a margin-negative resection, regardless of margin distance, provides similar local control rates (31) . Close margins may be encountered particularly in large truncal tumors as the ability to provide a margin-negative resection is complicated by the presence of adjacent critical anatomical structures necessitating a microscopic (R1) or macroscopic (R2) positive resection. Furthermore, R1 resections may still be curative as the patients undergoing R1 resection frequently do not demonstrate recurrent disease except when tumor characteristics are unfavorable (such as, high grade tumors) (3, 8, 14, 27, 29) . In such cases, local recurrence rate can be high, ranging from 30% in R1 resection vs. 10% in R0 resections. Consideration should be given for adjuvant radiotherapy in cases of R1 resection, particularly with high grade malignancies (3, 27, 32) .
Prognosis and the benefit of adjuvant treatment are greatly influenced by the final margin status of a resection. Prognosis following resection will be impacted by tumor type, but also heavily influenced by a number of additional considerations including grade, size and location (truncal/ retroperitoneal versus extremity). Patient considerations include nutritional status, comorbidities and overall performance status. Therefore, in patients presenting with a painless mass or a large truncal mass the diagnosis of STS must be considered (3, 12, 14, 26, 27, 29, 33) .
Surgical approach by location
In localized extremity tumors A multimodal approach that attempts to avoid extremity amputation has been pursued since the critical work of Rosenberg and coworkers (30) . Approaches to extremity sarcoma with limb-sparing resections tolerating R1 or R2 resections if critical structures like nerves are involved with the use of adjuvant radiation and possibly chemotherapy can obtain excellent local control rates in some cases exceeding 90%. Patient survival following limb-preservation actually appears to exceed that associated with amputation, and thoughtful limb-preserving resection can be associated with excellent functional status with no apparent defect in the majority of patients (34, 35) . Nonetheless, complications of resection and radiation can lead to significant problems in the extremity including severe edema, chronic wound formation and impaired functional capacity (36) (37) (38) .
Truncal sarcoma
Outcome for STS of the trunk are generally poorer than those of the extremity due to both more advanced stage at presentation and troublesome location that can make margin-negative extirpation difficult. Technical issues include dealing with the attainment of larger size and increased difficulty in obtaining negative margins due to invasion or intricate involvement with a number of vital structures that must be preserved. Local recurrence rates exceeding 30% may be expected and, in cases of very large, poor-prognosis sarcomas involving numerous critical structures, recurrence may be unavoidable and surgery is largely a palliative undertaking (39) . Postoperative complications to surgical extirpation are similar to those encountered around similar surgeries and the organs involved. Surgical complications can include bowel obstruction, nerve damage including asthenia, leg weakness, and impotence. Use of adjuvant or neoadjuvant chemotherapy or radiation therapy generally is associated with more complications including enteritis, peripheral neuropathy and scarring (4, 25, 32, 36, 40) .
Adjacent organ invasion and oligometastatic disease
Surgical extirpation of STS may involve the resection of organs that become invaded or compromised. The capacity to do so safely and preserve organ function remains a critical component of sarcoma surgery and may require resection of any combination of involved organs. As a general rule, facility of the surgical team to perform each organ-specific surgery will be required. The objectives in such scenarios remains obtaining a margin-negative resection, thus organpreserving approaches are critical (25, 41, 42) .
Importance of specialty centers to optimize patient outcomes
Optimizing care for sarcoma patients may best be done at centers with experience in their management, both in the operating room and with adjuvant therapies. Increased recurrence rates have been reported in patients who were referred to centers with expertise in sarcoma after definitive operation. Mortality rates and amputation rates have been demonstrated to be lower at specialty centers (43) . Specialty centers allow for multidisciplinary teams, as well as enrollment in clinical studies (12, (43) (44) (45) . Furthermore, preoperative planning with an experienced plastic surgeon can lead to improved cosmetic and functional outcomes (46) . Additional considerations regarding reconstruction are well described by Hadad et al. in this special issue (47) .
Therapeutic considerations: balancing surgery with adjuvant therapies
When patients present with sarcoma, the mainstay therapy remains surgery with a goal of providing a margin-negative resection of the malignancy. In instances where the tumor is not amendable to complete surgical extirpation, particularly in instances of high-grade malignancy, the use of adjuvant therapies including radiation therapy and chemotherapy should be considered.
Radiation
The role of radiation therapy (RT) for extremity sarcoma is well established as part of an integrated, limb-preserving approach to extremity sarcoma. Doses approaching 60 cGy and more are generally well tolerated and associated with excellent local control rates. The introduction of radiation and advanced reconstructive techniques has decreased limb amputation rates without sacrificing overall survival (30, 48) . While radiation can be performed either preoperatively or postoperatively with equivalent disease control, preoperative radiation is associated with improved wound healing and less late-term morbidity (49) . Complications of RT in the extremity include edema, failure of wound healing and increased risk of fracture. Care must be used in STS patients to minimize radiation to bones and risk of pathologic fracture (36, 37) .
The role of RT for the treatment of STS of the abdomen, chest and retroperitoneum is less well defined and must balance toxicity associated with RT, the intrinsic inability of solid organs to tolerate RT, and relatively high RT doses required to improve local control. RT dose is limited by sensitivities of adjacent normal tissues such as bowel, kidney, liver, and spinal cord. Similar to the treatment of extremity sarcoma, preoperative RT is preferred. New techniques are being developed to limit toxicity by sparing normal tissue (27, 32, 39) .
Role of chemotherapy
Early studies suggested soft tissue sarcoma prognosis was more dependent upon location and grade than sarcoma type. Subsequent examination, however, including both population-based analyses and molecular analyses of tumor mutations, have clarified that adjuvant chemotherapy for sarcoma and subsequent prognosis may be critically dependent upon tumor type (50) (51) (52) . Nonetheless, in many instances the best available chemotherapy may be identical for a variety of sarcoma types and may not provide any therapeutic benefit (53) .
The role of chemotherapy in the neoadjuvant setting is controversial; however, strong rationale and emerging data favors the use of conventional multi-agent chemotherapy in high-risk STS (54) . This is based on a recent randomized controlled trial comparing the role of conventional chemotherapy (anthracycline and ifosfamide) over histologically directed chemotherapy in high-risk extremity or trunk STS of the 5 most common histological subtypes (myxoid liposarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, leiomyosarcoma, and malignant peripheral nerve sheath tumor). The trial was stopped early after interim analysis showed a significant benefit in favor of conventional chemotherapy over histologically directed chemotherapy (55) . The use of neoadjuvant chemotherapy ultimately should be decided in a multidisciplinary tumor board based on individual patient risk and ability to tolerate chemotherapy. Surgery remains the only curativetreatment and central pillar of treatment the paradigm, but chemotherapy may have the potential to downsize the tumor leading to limb or organ sparing surgery besides offering theoretical advantages of limiting micrometastatic disease and in-vivo assessment to chemotherapy (56) .
Adjuvant chemotherapy has not been universally adopted except for osteosarcoma and Ewing sarcoma. The largest meta-analysis so far including 1,953 patients from 18 trials has shown a significant benefit in terms of local recurrence [odds ratio (OR) =0.73; 95% CI, 0.56-0.94; P=0.02], distant and overall recurrence (OR =0.67; 95% CI, 0.56-0.82; P=0.0001) in favor of chemotherapy with doxorubicin and ifosfamide (40) . The impact of chemotherapy on survival, however, is modest. Based upon the meta-analytic examination, a benefit is only observed with doxirubicin and ifosfamide with an absolute risk reduction of death from 46% to 40% (P<0.05). This has been estimated to translate into a number needed to treat of 17 to benefit one patient (40) . Therefore, adjuvant chemotherapy is reasonable especially for patients with high-risk STS who have not received neoadjuvant chemotherapy. Again, the decision to give chemotherapy should be individualized and made in a multidisciplinary tumor board. Furthermore, patients should be made aware of the limited demonstrated benefit in overall survival.
Molecular analyses to identify critical mutations that lead to the development of various sarcomas and the resultant use of targeted therapies have begun to improve outcomes for some patients. Today, select mechanistic breakthroughs and targeted therapies for specific sarcomas has resulted in dramatically different outcomes for certain specific tumor types. GIST, for example, has demonstrated a radical transformation in patient outcomes following the recognition that type III tyrosine kinase receptor mutations, particularly of cKit, are present in most GIST tumors and targeted therapies can be highly effective in their management (57) (58) (59) .
Phase II studies have begun to identify new therapies for specific sarcoma subtypes. This includes better therapies to treat different liposarcoma subtypes (including myxoliposarcoma) (60, 61) . However, due to the rarity of STS and its many subtypes, it is difficult to have enough power to evaluate chemotherapeutic response to individual subtypes, causing them to frequently be lumped together. For unresectable advanced STS, chemotherapy with a palliative intent (decrease symptoms and improve survival and quality of life) is usual treatment. Therefore, current the mainstay chemotherapeutic option for most STS remains an anthracycline usually doxorubicin, with or without an alkylating agent, usually ifosfamide with mesna or olaratumab (anti-PDGFRα antibody) (62) (63) (64) . Combination chemotherapy generally offers a higher response rate, however, responses are short-lived and OS benefit has not been clearly demonstrated for any combination in a phase III randomized clinical trial. A phase II trial combining olaratumab with doxorubicin has recently shown significant benefit in median PFS (6.6 vs. 4.1 months; HR =0.67; 95% CI, 0.44-1.02; P=0.05) as well as median OS (26.5 vs. 14.7 months; HR =0.46; 95% CI, 0.30-0.71; P=0.0003) and lead to an accelerated approval of olaratumab, but phase III data is awaited. Notably, a recent meta-analysis of multi-agent chemotherapy in advanced STS including 22 trials (phase II and III) from 1974 to 2016 showed that multi-agent chemotherapy was associated with significant improvement in OS (HR =0.79; 95% CI, 0.65-0.97; P=0.02) and modest improvement in PFS (HR =0.86; 95% CI, 0.73-1.00; P=0.05). However, subgroup analysis by anthracycline containing vs. non-anthracycline containing chemotherapy showed no difference in OS or PFS (65) .
Alternative therapies for anthracycline-insensitive subtypes: pigmented villonodular tenosynovitis, tenosynovial giant cell tumor, dermatofibrosarcoma protuberans, neoplasm with perivascular epithelioid cell differentiation, endothelioid hemangioendothelioma, solitary fibrous tumor, alveolar soft parts sarcoma, and extraskeletal myxoid chondrosarcoma with EWSR1-NR4A3 fusion, are summarized in Table 1 (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) . These therapies can be used neoadjuvantly to downsize tumors, adjuvantly, or to control unresectable disease. Unfortunately, these therapies have modest benefit. For example, in the case of doxorubicin plus olaratumab, progression free survival is increased by 2.5 months (4, 64) . Targeted therapies, such as those used for GIST are needed for other STS subtypes. Currently next generation sequencing is being implemented to discover potential drug targets (76) .
Prognostic factors
The most important prognostic factors are histologic grade, tumor size, and stage at the time of diagnosis. Local control is the key to a favorable outcome. Improved outcomes for patients with head and neck or extremity sarcomas are largely due to increased likelihood for earlier diagnosis, the ability to more easily excise many extremity tumors with negative margins, and a better ability to provide adjuvant radiotherapy at higher doses (3, 12, 14, 77) . A postoperative nomogram can be used to predict 12-year mortality (78) .
Conclusions STS is a rare, but increasingly common malignancy. Early diagnosis and referral to a specialized center are crucial for a favorable outcome due to the availability of expertise, multimodality treatment, and access to clinical trials. While advances in adjuvant therapies are being made, complete surgical excision remains the mainstay of therapy. Systemic therapies for STS subtypes other than GIST are limited in benefit; however, successful targeted therapies for GIST provide hope for novel therapies being developed.
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